Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors
- Author
- TABERNERO, Josep; ROJO, Federico; SHAND, Nicholas; MACARULLA, Teresa; RAMOS, Francisco Javier; DIMITRIJEVIC, Sasa; ZOELLNER, Ulrike; TANG, Pui; STUMM, Michael; LANE, Heidi A; LEBWOHL, David; BASELGA, José; CALVO, Emiliano; BURNS, Howard; JUDSON, Ian; HAZELL, Katharine; MARTINELLI, Erika; Y CAJAL, Santiago Ramon; JONES, Suzanne; VIDAL, Laura
[1] Medical Oncology and Pathology Departments, Vail d'Hebron University Hospital, Barcelona, Spain
[2] Medical Oncology Department, Sarah Cannon Cancer Center, Nashville, TN, United States
[3] Medical Oncology Department, Royal Marsden Hospital, London, United Kingdom
[4] Novartis Oncology, Basel, Switzerland
[5] Novartis Oncology, Florham Park, NJ, United States - Source
Journal of clinical oncology. 2008, Vol 26, Num 10, pp 1603-1610, 8 p ; ref : 50 ref
- ISSN
- 0732-183X
- Scientific domain
- Medical oncology
- Publisher
- Lippincott Williams & Wilkins, Baltimore, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Cancérologie Dose Essai clinique phase I Evérolimus Homme Stade avancé Traitement Tumeur solide Inhibiteur mTOR Pharmacodynamie Protein kinase mTOR Cancer Inhibiteur synthèse protéique Lactone Macrolide Tumeur maligne
- Keyword (en)
- Cancerology Dose Phase I trial Everolimus Human Advanced stage Treatment Solid tumor Pharmacodynamics Protein kinase mTOR Cancer Protein synthesis inhibitor Lactone Macrolide Malignant tumor
- Keyword (es)
- Cancerología Dosis Ensayo clínico fase I Everolimus Hombre Estadio avanzado Tratamiento Tumor sólido Farmacodinámica Cáncer Inhibidor síntesis proteica Lactona Macrólido Tumor maligno
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Discipline
- Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 20276610
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1200/JCO.2007.14.5482 
https://dx.doi.org/10.1200/JCO.2007.14.5482
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2007.14.5482\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1603\";s:8:\"\u0000*\u0000epage\";s:4:\"1610\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"TABERNERO\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Josep\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:14:\"ROJO, Federico\";i:1;s:15:\"SHAND, Nicholas\";i:2;s:17:\"MACARULLA, Teresa\";i:3;s:23:\"RAMOS, Francisco Javier\";i:4;s:18:\"DIMITRIJEVIC, Sasa\";i:5;s:16:\"ZOELLNER, Ulrike\";i:6;s:9:\"TANG, Pui\";i:7;s:14:\"STUMM, Michael\";i:8;s:13:\"LANE, Heidi A\";i:9;s:14:\"LEBWOHL, David\";i:10;s:14:\"BASELGA, Jos\u00e9\";i:11;s:15:\"CALVO, Emiliano\";i:12;s:13:\"BURNS, Howard\";i:13;s:11:\"JUDSON, Ian\";i:14;s:17:\"HAZELL, Katharine\";i:15;s:17:\"MARTINELLI, Erika\";i:16;s:23:\"Y CAJAL, Santiago Ramon\";i:17;s:14:\"JONES, Suzanne\";i:18;s:12:\"VIDAL, Laura\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2007.14.5482\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1603\";s:8:\"\u0000*\u0000epage\";s:4:\"1610\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"TABERNERO\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Josep\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:14:\"ROJO, Federico\";i:1;s:15:\"SHAND, Nicholas\";i:2;s:17:\"MACARULLA, Teresa\";i:3;s:23:\"RAMOS, Francisco Javier\";i:4;s:18:\"DIMITRIJEVIC, Sasa\";i:5;s:16:\"ZOELLNER, Ulrike\";i:6;s:9:\"TANG, Pui\";i:7;s:14:\"STUMM, Michael\";i:8;s:13:\"LANE, Heidi A\";i:9;s:14:\"LEBWOHL, David\";i:10;s:14:\"BASELGA, Jos\u00e9\";i:11;s:15:\"CALVO, Emiliano\";i:12;s:13:\"BURNS, Howard\";i:13;s:11:\"JUDSON, Ian\";i:14;s:17:\"HAZELL, Katharine\";i:15;s:17:\"MARTINELLI, Erika\";i:16;s:23:\"Y CAJAL, Santiago Ramon\";i:17;s:14:\"JONES, Suzanne\";i:18;s:12:\"VIDAL, Laura\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2007.14.5482\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2007.14.5482\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1603\";s:8:\"\u0000*\u0000epage\";s:4:\"1610\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"TABERNERO\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Josep\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:14:\"ROJO, Federico\";i:1;s:15:\"SHAND, Nicholas\";i:2;s:17:\"MACARULLA, Teresa\";i:3;s:23:\"RAMOS, Francisco Javier\";i:4;s:18:\"DIMITRIJEVIC, Sasa\";i:5;s:16:\"ZOELLNER, Ulrike\";i:6;s:9:\"TANG, Pui\";i:7;s:14:\"STUMM, Michael\";i:8;s:13:\"LANE, Heidi A\";i:9;s:14:\"LEBWOHL, David\";i:10;s:14:\"BASELGA, Jos\u00e9\";i:11;s:15:\"CALVO, Emiliano\";i:12;s:13:\"BURNS, Howard\";i:13;s:11:\"JUDSON, Ian\";i:14;s:17:\"HAZELL, Katharine\";i:15;s:17:\"MARTINELLI, Erika\";i:16;s:23:\"Y CAJAL, Santiago Ramon\";i:17;s:14:\"JONES, Suzanne\";i:18;s:12:\"VIDAL, Laura\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:24:\"10.1200\/JCO.2007.14.5482\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:178:\"Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors\";s:9:\"\u0000*\u0000jtitle\";s:28:\"Journal of clinical oncology\";s:9:\"\u0000*\u0000stitle\";s:14:\"J. clin. oncol\";s:7:\"\u0000*\u0000date\";s:4:\"2008\";s:9:\"\u0000*\u0000volume\";s:2:\"26\";s:8:\"\u0000*\u0000issue\";s:2:\"10\";s:8:\"\u0000*\u0000spage\";s:4:\"1603\";s:8:\"\u0000*\u0000epage\";s:4:\"1610\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0732-183X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:9:\"TABERNERO\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Josep\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:19:{i:0;s:14:\"ROJO, Federico\";i:1;s:15:\"SHAND, Nicholas\";i:2;s:17:\"MACARULLA, Teresa\";i:3;s:23:\"RAMOS, Francisco Javier\";i:4;s:18:\"DIMITRIJEVIC, Sasa\";i:5;s:16:\"ZOELLNER, Ulrike\";i:6;s:9:\"TANG, Pui\";i:7;s:14:\"STUMM, Michael\";i:8;s:13:\"LANE, Heidi A\";i:9;s:14:\"LEBWOHL, David\";i:10;s:14:\"BASELGA, Jos\u00e9\";i:11;s:15:\"CALVO, Emiliano\";i:12;s:13:\"BURNS, Howard\";i:13;s:11:\"JUDSON, Ian\";i:14;s:17:\"HAZELL, Katharine\";i:15;s:17:\"MARTINELLI, Erika\";i:16;s:23:\"Y CAJAL, Santiago Ramon\";i:17;s:14:\"JONES, Suzanne\";i:18;s:12:\"VIDAL, Laura\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:0:\"\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:178:\"Dose-and Schedule-Dependent Inhibition of the Mammalian Target of Rapamycin Pathway With Everolimus : A Phase I Tumor Pharmacodynamic Study in Patients With Advanced Solid Tumors\";s:8:\"\u0000*\u0000place\";s:13:\"Baltimore, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:1:\"8\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
